Literature DB >> 26838246

Cholangiocarcinoma Patient Outcome in Northeastern Thailand: Single-Center Prospective Study.

Vor Luvira1, Kasama Nilprapha, Vajarabhongsa Bhudhisawasdi, Ake Pugkhem, Nittaya Chamadol, Supot Kamsa-ard.   

Abstract

BACKGROUND: Cholangiocarcinoma is relatively rare worldwide. Most previous reports collected only patients with pathological diagnosis. In fact, however, many patients coming to hospital are diagnosed by clinical suspicion with radiologic imaging and receive treatment without histological confirmation. Real survival data and outcome of each treatment, especially for patients that do not have histologic confirmation, are lacking. In this study, therefore, we aimed to analyze the survival rates of CCA patients and the proportions of patients receiving different treatments.
MATERIALS AND METHODS: A total of 270 patients clinically suspected of CCA and visiting Srinagarind Hospital in May-July 2010, were prospectively followed until December 2014. After checking their clinical records, 163 of 270 patients were finally diagnosed as having CCA, and the data of this group were analyzed for survival rate and received treatments.
RESULTS: Of the 163 patients, 96 (58.9%) had intrahepatic, 56 (34.4%) had perihilar and 11 (6.7%) had distal CCA. The majority [107 (65.6%, 95%CI, 57.8-73.0)] received only supportive care. Overall median survival was 4 months (95%CI, 3.3-4.7), and 2-years survival was only 8.1% (95%CI,4.5-12.9). However, the 4 year survival of the R0 resection group was 100%.
CONCLUSIONS: The present results show that the prognosis of CCA is very poor in North-east Thailand. Most CCA patients receive only treatment to alleviate symptoms due to their advanced stage of disease. Complete surgical resection at the early stage is the only treatment that significantly improves patient survival.

Entities:  

Mesh:

Year:  2016        PMID: 26838246     DOI: 10.7314/apjcp.2016.17.1.401

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  25 in total

Review 1.  Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.

Authors:  Vor Luvira; Egapong Satitkarnmanee; Ake Pugkhem; Chumnan Kietpeerakool; Pisake Lumbiganon; Porjai Pattanittum
Journal:  Cochrane Database Syst Rev       Date:  2021-09-13

2.  Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.

Authors:  Supawan Jamnongsong; Patipark Kueanjinda; Pongsakorn Buraphat; Phuwanat Sakornsakolpat; Kulthida Vaeteewoottacharn; Seiji Okada; Siwanon Jirawatnotai; Somponnat Sampattavanich
Journal:  iScience       Date:  2022-09-23

3.  Emerging roles of GALNT5 on promoting EGFR activation in cholangiocarcinoma: a mechanistic insight.

Authors:  Marutpong Detarya; Worachart Lert-Itthiporn; Panupong Mahalapbutr; Methus Klaewkla; Supannika Sorin; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Wunchana Seubwai; Chaisiri Wongkham; Norie Araki; Sopit Wongkham
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand.

Authors:  Waritta Kunprom; Chaiwat Aphivatanasiri; Prakasit Sa-Ngiamwibool; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Walailak Bamrungkit; Malinee Thanee; Piya Prajumwongs; Watcharin Loilome; Narong Khuntikeo; Attapol Titapun; Apiwat Jareanrat; Vasin Thanasukarn; Tharatip Srisuk; Vor Luvira; Kulyada Eurboonyanun; Julaluck Promsorn; Supinda Koonmee
Journal:  Front Public Health       Date:  2022-05-16

5.  Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways.

Authors:  Michael J Viereckl; Kelsey Krutsinger; Aaron Apawu; Jian Gu; Bryana Cardona; Donovan Barratt; Yuyan Han
Journal:  Biomolecules       Date:  2022-06-20

6.  High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection.

Authors:  Attapol Titapun; Vor Luvira; Tharatip Srisuk; Apiwat Jareanrat; Vasin Thanasukarn; Malinee Thanee; Prakasit Sa-Ngiamwibool; Sureerat Padthaisong; Kassaporn Duangkumpha; Manida Suksawat; Watcharin Loilome; Paiboon Sithithaworn; Anchalee Techasen; Bandit Thinkhamrop; Alexa Dzienny; Ayse Caglayan; David Park; Simran Mahmud; Narong Khuntikeo
Journal:  Int J Gen Med       Date:  2021-06-01

7.  Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.

Authors:  Kwuntida U Kotepui; Sumalee Obchoei; Kulthida Vaeteewoottacharn; Seiji Okada; Sopit Wongkham; Kanlayanee Sawanyawisuth
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

8.  Morphological Classification of Intraductal Papillary Neoplasm of the Bile Duct with Survival Correlation

Authors:  Vor Luvira; Kulyada Somsap; Ake Pugkhem; Chalerm Eurboonyanun; Varisara Luvira; Vajarabhongsa Bhudhisawasdi; Chawalit Pairojkul; Supot Kamsa Ard
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

9.  Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy

Authors:  Skolchart Pongmaneratanakul; Suebpong Tanasanvimon; Thitima Pengsuparp; Nutthada Areepium
Journal:  Asian Pac J Cancer Prev       Date:  2017-03-01

10.  Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo.

Authors:  Jeerati Prompipak; Thanaset Senawong; Banchob Sripa; Albert J Ketterman; Suppawit Utaiwat; Khanutsanan Woranam; Jarckrit Jeeunngoi; Gulsiri Senawong
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.